Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Virus or bacteriophage
Patent
1996-01-29
1997-11-18
Knode, Marian C.
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Virus or bacteriophage
4352351, 435239, A61K 3576, C12N 702, C12N 708
Patent
active
056885016
ABSTRACT:
The present invention is directed to bacteriophage therapy, using methods that enable the bacteriophage to delay inactivation by any and all parts of the host defense system (HDS) against foreign objects that would tend to reduce the numbers of bacteriophage and/or the efficiency of those phage at killing the host bacteria in an infection. Disclosed is a method of producing bacteriophage modified for anti-HDS purposes, one method being selection by serial passaging, and the other method being genetic engineering of a bacteriophage, so that the modified bacteriophage will remain active in the body for longer periods of time than the wild-type phage.
REFERENCES:
patent: 4332897 (1982-06-01), Nakano et al.
patent: 4375734 (1983-03-01), Kozloff et al.
patent: 4797363 (1989-01-01), Teodorescu et al.
patent: 4865979 (1989-09-01), Nakano et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 4957686 (1990-09-01), Norris
patent: 5132221 (1992-07-01), Ward et al.
patent: 5344822 (1994-09-01), Levine et al.
ATCC Catalogue of Bacteria and Phages, 18th ed., 1992, ATCC Rockville, MD, pp. 402-409.
Smith, H.W. et al., "J. of Gen. Micro," vol. 133, 1987, pp. 1111-1126.
Smith, H.W. et al., "J. of Gen. Micro," vol. 128, 1982, pp. 307-318.
Smith, H.W. et al., "J. of Gen. Micro," vol. 129, 1983, pp. 2659-2675.
Weber-Dabrowska et al., Studies on bacteriophage penetration in patients subjected to phage therapy. Archivum Immunologiae et Therapiae Experimentalis 35:563-568, 1987.
Merril et al., Long-circulating bacteriophage as antibacterial agents. Proc. Natl. Acad. Sci. USA 93:3188-3192, 1996.
Soothill, "Treatment of experimental infections of mice with bacteriophages", J. Med. Micro., vol. 37, 258-261 (1992).
Berchieri et al., "The activity in the chicken alimentary tract of bacteriophages lytic for Salmonella typhimurium", Res. Micro., 142, 541-549 (1991).
Roitt, Essential Inmuno., 7th Ed., pp. 110-113, 1991.
Bogovazova et al., "Immunobiological Properties and Therapeutic Efficacy of Preparations of Klebsiella Bacteriophages", Jour. Micro., Epidem. and Immuno., vol. 3, pp. 30-33, 1992.
Geier et al., "Fate of Bacteriophage Lambda in Non-innune Germ-free Mice", Nature, vol. 246, No. 5430, pp. 221-222 (1973).
Salmon et al., "Staphage Lysate Therapy in Chronic Staphylococcal Infections", Jour. of Med. Soc. of NJ, vol. 60, pp. 188-193 (1963).
Angel et al., "Beneficial Effects of Staphage Lysate in the Treatment of Chronic Recurrent Hidradenitis suppurativa", Surgical Forum 38:111-112, 1987.
Kress, "A Preliminary Report on the Use of Staphage Lysate for Treatment of Hidradenitis suppurativa", Annals of Plas. Surg. vol 6, No. 5, (1981) pp. 393-395.
Nucci et al., "The therapeutic value of poly(ethylene glycol)-modified proteins", Adv. Drug Del. Reviews, 6, 133-151 (1991).
Huang, "Stealth Liposomes.TM., Ninja Liposomes, or Cryptosomes: Are they Really Sterically Stabilized Liposomes?", Jour. of Liposome Res., vol. 2, No. 3, 451-454 (1992).
Haywood, "Fusion of Sendai Viruses with Model Membranes", J. Mol. Biol., vol. 87, 625-628, (1974).
Ghosh et al., "Grafting of Different Glycosides on the Surface of Liposomes and its Effect on the Tissue Distribution of .sup.125 I-Labelled .gamma.-Globulin Encapsulated in Liposomes", Biochimica et Biophysica Acta, vol. 632 (1980) pp. 562-572.
Mori et al., "Influence of the Steric Barrier Activity of Amphipathic Poly(ethyleneglycol) and Ganglioside GM.sub.1 on the circulation time of Liposomes and on the Target Binding of Immunoliposomes in Vivo", 1991 Federation of European Biochemical Societies, vol. 284, No. 2, pp. 263-266.
Lee et al., "Recognition of Liposomes by Cells: In Vitro Binding and Endocytosis Mediated by Specific Lipid Headgroups and Surface Charge Density", Biochimica et Biophysica Acta, vol. 1103 (1992) pp. 185-197.
Namba et al., "Glucuronate-Modified Liposomes with Prolonged Circulation Time", Chem. Pharm. Bull, vol. 38 No. 6 (1990) pp. 1663-1666.
Liu et al., "Role of Liposome Size and RES Blockade in Controlling Biodistribution and Tumor Uptake of GM.sub.1 -containing Liposomes", Biochimica et Biophysica Acta, vol. 1104 (1992) pp. 95-101.
Ackerman et al. Viruses of Prokaryotes, Volume 1: General Properties of Bacteriophages, "Main Indication of Phage Therapy," CRC Press (1987) pp. 151-155.
Engel et al., "The Preservation of Mycobacteriophages by Means of Freeze Drying", American Review of Respiratory Disease, vol. 109 (1974) pp. 561-566.
Cislo et al., "Bacteriophage Treatment of Suppurative Skin Infections", Archivum Immunologiae et Therapiae Experimentalis, 1987, vol. 35, pp. 175-183.
Slopek et al., "Results of Bacteriophage Treatment of Suppurative Bacterial Infections III. Detailed Evaluation of the Results Obtained in Further 150 Cases", Archivum Immunologiae et Therapiae Experimentalis, 1984, vol. 32, pp. 317-335.
Slopek et al., "Results of Bacteriophage Treatment of Suppurative Bacterial Infections IV. Evaluation of the Results Obtained in 370 Cases", Archivum Immunologiae et Therapiae Experimentalis, 1985, vol. 33, pp. 219-240.
Slopek et al., "Results of Bacteriophage Treatment of Suppurative Bacterial Infections VI. Analysis of Treatment of Suppurative Staphylococcal Infections", Archivum Immunologiae et Therapiae Experimentalis, 1985, vol. 33, pp. 261-273.
Kucharewicz-Krukowska et al., "Immunogenic Effect of Bacteriophage in Patients Subjected to Phage Therapy", Archivum Immunologiae et Therapiae Experimentalis, 1987, vol. 35, pp. 553-568.
Harwood, J.L., "Understanding Liposomal Properties to Aid Their Clinical Usage", Trends in Biochemical Sciences vol. 17, (1992) pp. 203-204.
Mazacek et al.., "Die Bakteriophagie in der Therapie und Prophylaxe der Infektionskranheiten," Eingegangen am 23, Nov. 1968, pp. 385-394.
Molin et al., "Suicidal Genetic Elements and Their Use in Biological Containment of Bacteria", Annu. Rev. Microbiol., 47:139-66 (1993).
Stribling et al., "Aerosol gene delivery in vivo", Proc. Natl. Acad. Sci. vol. 89, pp. 11277-11281, 1992.
Lee et al., "Site-specific integration of mycobacteriophage L5: Integration-porficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guerin.," Proc. Natl. Acad. Sci., vol. 88, pp. 3111-3115, 1991.
Kalpana et al., "Insertional mutagenesis and illegitimate recombination in mycobacteria", Proc. Natl. Acad. Sci., vol. 88, pp. 5433-5437, 1991.
Poste et al., "Activation of Tumoricidal Properties in Macrophages by Liposome-encapsulated Lymphokines: in vitro Studues", Liposomes and Immunobiology, pp. 93-161, 1980.
Lewis et al., "Specific Antibody-Dependent Macrophage Phagocytosis of Lipid Vesicles Containing Lipid Hapten", Liposomes and Immunobiology, pp. 179-191, 1980.
Bangham, "Liposomes: Realizing Their Promise", Hospital Practice pp. 51-52, 1992.
Baker, "Treatment of Chronic Bronchial Asthma, Aerosol of Staphylococcus Bacteripohage Lysate as an Adjunct to Systemic Hyposensitization" Am. Prac. & Digest of Treatment, vol. 9, No. 4, pp. 591-598, 1958.
Mudd et al., "Nonspecific Cell-Mediated Immunity in the Treatment of Recurrent Herpesvirus and Aphthous Ulcers", Proceedings of the First Intersectional Congress of IAMS, vol. 4, 1975.
Shayegani et al., "Correlation of Staphylococci-Induced Delayed-Type Hypersensitivy and Nonspecific Resistance During Their Development, Long-Term Duration and Adoptive Transfer", Jour. of the Reticu. Soc., vol. 28, No. 3, pp. 265-274, 1980.
Neuberger, "Past and Present Concepts of Glycoproteins", Glycoproteins of Blood Cells & Plasma, Lippincott & Co., (1972), pp. 1-15 and 282-301.
Anstee, "The Blood Group MNSs-Active Sialoglycoproteins", Seminars in Hematology, vol. 18, No. 1, pp. 13-31, 1981.
Furthmayr, "Structural comparison of glyphorins and immunochemical analysis of genetic variants", Nature, vol. 271, pp. 519-524, 1978.
Borrebaeck, "Strategy for the production of human monoclonal antibodies using in vitro activated B cells", Jour. of Immun. Methods, 123 157-165, 1989.
Dixon, "Scientifically Speaking", British Med. Jour., vol. 294, p. 1168, 1987.
Ho et al., "Target-sensitive Immunoliposomes as an Efficient Drug Carrier for An
Adhya Sankar L.
Carlton Richard M.
Merril Carl R.
Exponential Biotherapies, Inc.
Knode Marian C.
The United States of America as represented by the Secretary of
Wortman Donna C.
LandOfFree
Antibacterial therapy with bacteriophage genotypically modified does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibacterial therapy with bacteriophage genotypically modified , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibacterial therapy with bacteriophage genotypically modified will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1563718